Tests a synbiotic formula SGR11 in adults with inflammatory bowel disease
Tests a gut-supporting synbiotic, SGR11, in adults with inflammatory bowel disease.
Plain-language title generated from the registry record
Registry title: A Pilot Study on the Efficacy and Safety of a Novel Synbiotic Formula (SGR11) in Patients With Inflammatory Bowel Disease (IBD)
Key facts
- Where
- Hong Kong, Hong KongSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07411131, who can take part
Where in Hong Kong
- Prince of Wales HospitalHong Kong, Hong KongNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT07411131
- Record updated
- 13 February 2026
- Original description
The goal of this clinical trial is to find out whether a synbiotic formula (SGR11) can improve symptoms and health measures in people with inflammatory bowel disease (IBD). The main questions it aims to answer are:Read full original descriptionShow less
A Pilot Study on the Efficacy and Safety of a Novel Synbiotic Formula (SGR11) in Patients With Inflammatory Bowel Disease (IBD)
The goal of this clinical trial is to find out whether a synbiotic formula (SGR11) can improve symptoms and health measures in people with inflammatory bowel disease (IBD). The main questions it aims to answer are:
* Does SGR11 lead to overall improvement in a participant's condition after 8 weeks, as measured by the Clinical Global Impression-Improvement Scale (CGI I)? * Is SGR11 safe and well tolerated in people with IBD?
Participants will:
* Take the study synbiotic formula (SGR11) daily for 8 weeks * Complete symptom and quality of life questionnaires * Provide stool samples and, if applicable, blood samples to measure inflammation and gut microbiome changes * Report any side effects that occur during the study
Inclusion: Individuals aged between 18-75; Chinese ethnicity; Confirmed diagnosis of ulcerative colitis (UC) with mild to moderate disease activity, defined as a Simple Clinical Colitis Activity Index (SCCAI) of 3-5; On stable doses of IBD medication for ≥4 weeks prior to enrolment; Ability to provide written informed consent; Willingness to comply with study procedures.
Exclusion: Known history of severe organ failure (including decompensated cirrhosis, malignant disease, kidney failure, epilepsy, active serious infection, acquired immunodeficiency syndrome); Known allergy or intolerance to study components; Severe active IBD requiring hospitalization; Presence of an ileostomy or colostomy; Severe comorbidities or immunocompromised states; Known current sepsis; Recent use of antibiotics, probiotics, or prebiotics within 4 weeks; Known pregnancy or breastfeeding; Inability to receive oral fluids; Participation in other interventional clinical trials within 30 days.